Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
about
Management issues with exogenous steroid therapyIntravenous zoledronate for osteoporosis: less might be moreGlucocorticoid-induced osteoporosisManaging Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral ResearchManagement of endocrine disease: Secondary osteoporosis: pathophysiology and managementDo bisphosphonates cause femoral insufficiency fractures?Lipid metabolism disorders and bone dysfunction--interrelated and mutually regulated (review)Recognizing and treating secondary osteoporosis2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summaryAn overview and management of osteoporosisManagement of glucocorticoid-induced osteoporosis: clinical data in relation to disease demographics, bone mineral density and fracture risk.UK clinical guideline for the prevention and treatment of osteoporosisAn observational study of musculoskeletal pain among patients receiving bisphosphonate therapyIs bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled studyEfficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis.Development of clinical utility of zoledronic acid and patient considerations in the treatment of osteoporosisAmerican Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosisRecent advances in managing osteoporosis.Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid.A practical guide to the monitoring and management of the complications of systemic corticosteroid therapyMedication-induced osteoporosis: screening and treatment strategiesZoledronic acid: clinical utility and patient considerations in osteoporosis and low bone massGlucocorticoid-induced osteoporosis in rheumatic diseases.A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis.Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group ReportBisphosphonates for steroid-induced osteoporosis.Role of zoledronic acid in the prevention and treatment of osteoporosis.Updated recommendations for the diagnosis and management of osteoporosis: a local perspectiveSafety and tolerability of zoledronic acid and other bisphosphonates in osteoporosis management.Prevention of glucocorticoid induced bone changes with beta-ecdysone.Raman spectroscopy detects deterioration in biomechanical properties of bone in a glucocorticoid-treated mouse model of rheumatoid arthritis.Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medicationsOsteoporosis in men: a review.Bisphosphonates and glucocorticoid-induced osteoporosis: cons.Glucocorticoid-induced osteoporosis - a disorder of mesenchymal stromal cells?Zoledronic acid-induced hepatotoxicity relieved after subsequent infusions in a Chinese woman with glucocorticoid-induced osteoporosisTreatment of glucocorticoid-induced osteoporsisZoledronic Acid for the treatment and prevention of primary and secondary osteoporosis.Glucocorticoid-induced osteoporosis: treatment update and review.Aging and bone loss: new insights for the clinician.
P2860
Q24564449-67B5DB0D-8128-4EF1-8290-D4282650A222Q26738958-06C69BC6-ABCC-479A-AD7F-F7B4C96E2A0FQ26778272-19E44DBA-DD66-4851-B10B-765A72D862A2Q26782621-C119C3E5-52F2-42B5-ABE4-41938DA213E5Q26998249-A6804AFD-2BAA-49AE-8C37-6BE560C1208EQ27021396-9EE3A00C-ECE4-4036-8505-BED1F1CAD118Q28083206-58F704F4-42BA-4FBD-B382-B3E4AED3988EQ28270738-A3E7C8D6-1674-4A2C-876A-4CC467762E25Q28295416-79A077DD-95F6-4DF3-987E-EFB045E07A6AQ30235274-73C7B9CC-0DDE-4B73-82A5-1D6CA53E7501Q30946308-2941F7F8-5FA4-47C3-B329-825AD04E8186Q33581078-5EAC67FA-9B36-48B5-8373-5ED26D95303FQ33765055-A749BD81-9174-4CFA-9961-7BA0610EFC54Q33866456-B331CEBB-A958-4656-A92D-F39437910BB7Q33886852-60F00DAF-9AB5-4DBD-8E70-69244ADE0F7CQ34042003-0BA5862F-6D10-4E2C-97DA-825FEDF2A7BAQ34158441-AD0D004A-B6FC-4E27-A5D8-0E225BF849FDQ34167436-C11139B4-D459-4B8A-BC95-B2D15E788AD2Q34346425-D484D35C-747C-4503-860C-275999716F65Q34364143-94B3E2FC-9712-4E6B-869B-76D0B43E1685Q34389358-2D9C5CF3-9BE8-49DE-A37E-08C85137FF95Q34389524-533134CA-41A8-486E-B390-537BA25A52E1Q34394081-4D72531C-5D32-47BA-96F1-C5D8DBF4D8F9Q34413330-F839B496-9DA2-497B-8F1E-5FEBD8205F03Q34486831-53F1AF2E-6199-4B5C-9BDA-104B9F091CBCQ34542004-0364896F-0B68-4B76-948B-DFF71EEB78AEQ34984177-6401E3B8-98A5-4876-A234-F40956EC41F0Q35008617-306FCA98-96E9-4D8B-BC73-D2B069ED0CA0Q35026446-1603919F-580F-4ACF-B574-4C968C210FB1Q35163490-2808AB1D-4056-40A3-BB04-312E992915EFQ35206592-9EB33FAD-E401-47B8-94AE-5B7BE0AE846BQ35740351-7F596DC8-23AD-4AD0-99FE-3D0829E78C66Q35755160-B8B379BF-A4FC-470B-9043-20F03B5CFC44Q35882427-3632ADF8-441D-47CC-A5C7-C147F867B094Q35972062-6C37EEA7-2662-4523-8ADC-24AA9B47CB8CQ35986961-CA8B7C2F-048A-4579-A242-A021225E954BQ36056932-64D85A6C-A686-44D9-A6C2-73AAD6165810Q36059331-7EF70800-55EA-480D-BCE5-FEA30EB59246Q36059394-2F6EB7AC-1F81-406F-BA7A-6095238EA6F5Q36059521-C69B16D5-3CA5-4F30-B38D-37C74A7D3B3B
P2860
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Zoledronic acid and risedronat ...... , randomised controlled trial.
@en
Zoledronic acid and risedronat ...... , randomised controlled trial.
@nl
type
label
Zoledronic acid and risedronat ...... , randomised controlled trial.
@en
Zoledronic acid and risedronat ...... , randomised controlled trial.
@nl
prefLabel
Zoledronic acid and risedronat ...... , randomised controlled trial.
@en
Zoledronic acid and risedronat ...... , randomised controlled trial.
@nl
P2093
P1433
P1476
Zoledronic acid and risedronat ...... , randomised controlled trial.
@en
P2093
Alberto Ferreira
Chak-Sing Lau
Christian Roux
David M Reid
Florian Hartl
HORIZON investigators
Jean-Pierre Devogelaer
Kenneth Saag
Peter Mesenbrink
Philemon Papanastasiou
P304
P356
10.1016/S0140-6736(09)60250-6
P407
P577
2009-04-01T00:00:00Z